Current and future treatment approaches for neuromyelitis optica. - Wikidata - awgldk - TriplyDB

Current and future treatment approaches for neuromyelitis optica.

Current and future treatment approaches for neuromyelitis optica.

http://www.wikidata.org/entity/Q37892874

about

Aquaporin 4 and neuromyelitis optica An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives Inflammatory Optic Neuritis: From Multiple Sclerosis to Neuromyelitis Optica Update on neuromyelitis optica: natural history and management.Potential therapeutic benefit of C1-esterase inhibitor in neuromyelitis optica evaluated in vitro and in an experimental rat model Current options for the treatment of optic neuritis.Seronegative neuromyelitis optica after cardiac transplantation.Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels.Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody.Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase Immunological follow-up of patients with neuromyelitis optica: is there a good biomarker?The impact of diagnostic criteria for neuromyelitis optica in patients with MS: a 10-year follow-up of the South Atlantic Project.Novel advances in the diagnosis and treatment of neuromyelitis optica: is there a need to redefine the gold standard?Sex disparities in neuro-ophthalmologic disorders.Acquired pathology of the pediatric spine and spinal cord.Th17 cells in neuromyelitis optica spectrum disorder: a review.Neuromyelitis Optica (Devic's Syndrome): an Appraisal.Role of low plasma volume treatment on clinical efficacy of plasmapheresis in neuromyelitis optica.Plasma exchange for steroid unresponsive Devic's disease.Life on hold: the experience of living with neuromyelitis optica.Neuromyelitis optica in patients with coexisting human immunodeficiency virus infections.Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT Autoimmune Diseases Working Party.Importance of Regular and Maintenance Therapy Adherence in Neuromyelitis Optica (NMO): Lessons from a Repeating Relapse Case.Clinical features and sera anti-aquaporin 4 antibody positivity in patients with demyelinating disorders of the central nervous system from Tianjin, China.Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica

P2860

Q24613666-64455699-C259-4673-80E8-75C391C3980B Q26748601-03B38819-9469-4A14-90BD-B8DB77F41932 Q26767391-4CFE7752-EECA-401A-AFB1-0456273B01AB Q31160004-54B4F77B-60CE-48EF-AC31-03E1EB05E73C Q33702126-32908C43-B6EC-47FB-B9A7-B66511BB0CDE Q34142474-058DC072-8A3F-4527-BA38-976B3C8275AA Q36173222-9537153D-7323-422A-9B06-9815925BE64A Q36368530-E5AB101F-FFA5-4B97-85E5-9F1238315006 Q36528736-5AC4C69D-BDEB-4C85-95D1-F9A6F3C3601D Q36596808-E8027008-431C-4CEC-A6F4-863523C60C37 Q36852554-7CA599D6-366A-4CEA-B08E-AD86799D4FCB Q38061621-779C5487-4C58-4378-AAFA-1236042B974A Q38130899-A53BD9C7-2EFD-461D-B3AA-6DEC52D720D6 Q38152822-729CDB1D-7A84-4FAD-97A7-0607250139D4 Q38218704-EF9E80BA-65F9-461E-8AAE-87921AD67465 Q38582356-384FF865-8507-48E8-988C-ABF91C4809D0 Q38765404-868D192A-7182-4713-8882-8B6364E11276 Q38893206-9EC94138-C323-4580-9335-DBA16C005F03 Q42143005-865C031F-2BBD-4BCA-AF90-CB18351CAB69 Q43246789-6A9481F4-D325-4AD0-9BCC-C56DAACD5C56 Q44299516-F3ABB089-CB95-4A7B-BA22-C094E1FCABFE Q45018598-8F41A9B3-7323-42DC-99AF-5F4F0B755CAC Q45867293-12474D2F-935B-4BCB-A04F-9749AF3EE77C Q47555447-B84570E2-F2BC-41FF-A346-5454C0626BA5 Q47927193-41275593-E2FC-4BF1-861A-1604DF10D624 Q57267894-5731D0AC-761E-4839-ACD0-B1977217312C

P2860

Current and future treatment approaches for neuromyelitis optica.

http://www.wikidata.org/entity/Q37892874

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Current and future treatment approaches for neuromyelitis optica.

@en

Current and future treatment approaches for neuromyelitis optica.

@nl

type

label

Current and future treatment approaches for neuromyelitis optica.

@en

Current and future treatment approaches for neuromyelitis optica.

@nl

prefLabel

Current and future treatment approaches for neuromyelitis optica.

@en

Current and future treatment approaches for neuromyelitis optica.

@nl

P1433

Q37892874-FED9FE88-ADD0-414F-90FA-12D2C33EDCF7

P1476

Q37892874-BB81BEEB-2F33-40F2-96F6-698DAAE15683

P2093

Q37892874-605367B8-662B-4E29-BE00-516C82847A76

Q37892874-CD21577E-648F-4D61-A0F4-F3750EC8B03D

P2860

Q37892874-02CB30D1-4BDE-49BC-9C45-36644F2E2866

Q37892874-07DCAAA8-B460-44E7-A690-C76FCF836597

Q37892874-1081434D-2A65-4997-8B20-3E4580435B17

Q37892874-112D6B76-3690-49FB-AD29-153EB4EEFA45

Q37892874-11A10AE9-4FB1-4F4A-B35A-3DADFD6FB180

Q37892874-122AF5EB-6EC4-4BEA-B273-CB05410E4EE5

Q37892874-14F786BB-A544-4CE7-A5AB-13442A54F207

Q37892874-1A09FB3C-0CD9-4CF7-99C2-E995965806AF

Q37892874-25873638-B5B3-480A-8E8E-8159839F97C1

Q37892874-2E5A2780-894E-453E-9859-2FEBA4C3E50C

P304

Q37892874-2F40829B-E74D-4A3C-A26D-0E093DE9826B

P31

Q37892874-F6C11D59-4291-4BA8-B4E4-88EDF0D8DB13

P356

Q37892874-A7DA4F0F-8A27-4568-88F7-2450DFD9AF8D

P433

Q37892874-866507FE-9F62-4AA1-AAA5-4A8DF20266E4

P478

Q37892874-C4CA5895-DFFC-4C55-B93E-727C9995C3FA

P577

Q37892874-97B85497-8CE6-4E16-83C1-9BC126B16C54

P5875

Q37892874-7DA4D513-8E82-48D2-852F-691E9A0D4177

P698

Q37892874-5F8F53BE-085C-4217-A5AE-1102672AA4E6

P932

Q37892874-8D814848-6737-4A2D-A0DD-3AAF8BBCCEFA

P356

1756285611398939

P1433

Therapeutic advances in neurological disorders

P1476

Current and future treatment approaches for neuromyelitis optica.

@en

P2093

Jérôme de Seze

http://www.w3.org/2001/XMLSchema#string

Nicolas Collongues

http://www.w3.org/2001/XMLSchema#string

P2860

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

BIOLOGICAL ACTIVITIES OF C1 INHIBITOR

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

The clinical course of neuromyelitis optica (Devic's syndrome).

Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus.

A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

Mycophenolate mofetil and its mechanisms of action.

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.

P304

111-121

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1756285611398939

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51239972

http://www.w3.org/2001/XMLSchema#string

P698

21694808

http://www.w3.org/2001/XMLSchema#string

P932

3105616

http://www.w3.org/2001/XMLSchema#string